Acrux Limited · ASX:ACR
Acrux — Corporate Update (April 2026)
18 slides from Acrux's corporate update, April 2026
Slide 1: Strategic Update
Strategic Update April 2026
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements which are identified by words such as ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘expects’, or ‘intends’ and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and op
Slide 3: Female Testosterone
Female Testosterone Helping millions of women with Hypoactive Sexual Desire Dysfunction (HSDD) 3
Slide 4: Testosterone is not simply a male hormone but also important in women
“Testosterone is not simply a male hormone but is also an important hormone in women. Low sexual desire is the most prevalent sexual concern amongst women. When sufficient to cause personal distress women are considered as having hypoactive sexual desire dysfunction Professor Susan R Davis or HSDD.
Slide 5: Female Testosterone catalyses investment proposition
Female Testosterone catalyses investment proposition Phase III Ready Asset Significant, Fast-Growing Market Early Mover Advantage Phase I & Phase II Clinical Trials have ~4.9m US menopausal women suffer from There is no existing Female Testosterone treatment demonstrated a strong efficacy and safety
Slide 6: HSDD: Problem and Solution
HSDD: Problem and Solution What is Hypoactive Sexual Desire Disorder? Benefits of treating HSDD with Testosterone • HSDD affects ~4.9m menopausal women • HSDD efficacy in postmenopausal women in the US. demonstrated in 36 randomised clinical • HSDD impacts ~10% of all adult women, trials. most commo
Slide 7: Significant Global Market Opportunity
Significant Global Market Opportunity Approximately 60 million women in the US are affected by menopause with an estimated 4.9 million menopausal women suffering from HSDD. Acrux estimates the US menopausal market for HSDD alone could deliver a commercial value of ~US$2.88 billion per annum. Already
Slide 8: Female Testosterone Awareness
Female Testosterone Awareness Female Testosterone is gaining significant mainstream patient population awareness and traction across key global markets. Acrux Ltd (ASX:ACR) | Strategic Update | April 2026 8
Slide 9: Female Testosterone: A New Global Market for Acrux
Female Testosterone: A New Global Market for Acrux Acrux has significant IP in testosterone products, regulatory engagement and transdermal spray application technology and is uniquely positioned to exploit global demand for female testosterone products. Acrux has had positive engagement with the US
Slide 10: Acrux Proven MDTS Technology
Acrux Proven MDTS Technology Acrux’s proven Meter Dose Transdermal System (MDTS) technology is an ideal mode of administration for Female Testosterone. The spray is applied to the abdomen, reducing the risk of incidental contact and transfer on other parts of the body. Utilising the same delivery te
Slide 11: Female Testosterone Strategy
Female Testosterone Strategy Acrux will seek to co-develop the Female Testosterone solution to enable an expedited pathway through the proposed Phase III trial and ensure a fast market entry. Given no product is currently registered in the US with female appropriate dosing Acrux has a unique opportu
Slide 12: Development Roadmap: Target FY28 Market Launch
Development Roadmap: Target FY28 Market Launch • Acrux is focused on progressing potential co-development partnerships in the near-term to de-risk the clinical trial process and expedite market launch. • Acrux is well positioned with existing distribution and product agreements in place with potenti
Slide 13: Commercialised Portfolio
Commercialised Portfolio 13
Slide 14: Successful development and FDA registration of topical pharmaceuticals now generates core Acrux income
Successful development and FDA registration of topical pharmaceuticals now generates core Acrux income FDA registered products commercialised in the US • Nitroglycerin 0.4% ointment launched. Powerful Partnerships • Dapsone 5.0% gel launched. • Dapsone 7.5% gel launched. • Evamist® royalties continu
Slide 15: Generic Portfolio Revenue Performance
Generic Portfolio Revenue Performance • Acrux continues to generate strong financial performance License revenues from Generic portfolio from the Company’s portfolio of generic pharmaceuticals 2.5 that supports and subsidises group R&D activities. Q1 Q2 Q3 Q4 • Quarterly revenues from product licens
Slide 16: Summary
co © 'S Ss S an
Slide 17: Female Testosterone catalyses Acrux's investment proposition
Female Testosterone catalyses Acrux’s investment proposition • Phase III ready asset. • Significant, fast-growing market. • Early mover advantage. • Patient preferred application. • Co-development pathway. • Existing commercial portfolio. • IP & know-how. Acrux Ltd (ASX:ACR) | Strategic Update | Apr
Slide 18: Highly Experienced Executive Team
Highly Experienced Executive Team John Warmbrunn, BSc, MBA Felicia Colagrande, BSc(Hons), MBA CEO and Managing Director Product Development and Technical Affairs Director • Joined Acrux in 2025. • 25 years industry experience. • 25 years with Acrux. • 36 years industry experience. Joanna Johnson, BE